Iovance Biotherapeutics Inc to Discuss the Pooled Analysis of Cohorts 2 and 4 of the C-144-01 Study Transcript
All right. I [would] ask if this thing is on, but obviously, it is. Good evening, everyone. My name is Friedrich Finckenstein, and I'm the Chief Medical Officer of Iovance. So welcome to our in-person and virtual event to review the clinical data highlights for our lead TIL therapy, lifileucel, in advanced melanoma. The results, as I'm sure you're aware, were presented earlier today by our lead investigator, Dr. Amod Sarnaik of the Moffitt Cancer Center, during a rapid oral presentation at the SITC meeting.
The presentation includes efficacy results in 153 patients. across 2 consecutively enrolled cohorts on study C-144-01. These results are the basis for our ongoing biologics license application, or BLA, submission for lifileucel, which we are very excited about. The Iovance leadership team is grateful to be joined by Dr. Sarnaik and a panel of key opinion leaders within the field to hear their perspectives on the data.
This is the agenda for today's call. Let's see -- that works too. That's good. First,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
